In this issue of JAMA Ophthalmology, Linz et al1 investigate the preference values and treatment preferences of patients with vitreomacular interface abnormalities (VIA) in 3 countries. To do this, they used the Vision Preference Value Scale, which was first validated in 2004 in the Submacular Surgery Trial2 to measure the value that patients place on their vision. Interestingly, the study by Linz et al found similar results among patients from Thailand, the United Kingdom, and the United States. The authors justifiably conclude that their study has important implications for future research and for the delivery of patient-centered eye care. However, the authors do not go into great detail describing these implications, which are worthy of further consideration.